Completed PHASE1 INTERVENTIONAL 2-arm NCT01757795

Safety, Tolerability and Pharmacokinetics of SP-8203

A Phase I Single-Center, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8203

Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Conditions Ischemic Stroke

Interventions Placebo SP-8203

Updated 8 times since 2017 Last updated: Jul 20, 2020 Started: Dec 23, 2013 Primary completion: Mar 11, 2015 Completion: Mar 11, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01757795, this PHASE1 trial focuses on Ischemic Stroke and remains completed. Sponsored by Shin Poong Pharmaceutical Co. Ltd., it has been updated 8 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2020 — Jan 2021 [monthly]

Completed PHASE1

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Jun 2018 — Aug 2020 [monthly]

Unknown Status PHASE1
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE1
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE1

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shin Poong Pharmaceutical Co. Ltd.

Data source: Shin Poong Pharmaceutical Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea